Compare IPCA Labs with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ALEMBIC PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ALEMBIC PHARMA IPCA LABS/
ALEMBIC PHARMA
 
P/E (TTM) x 23.3 16.3 143.5% View Chart
P/BV x 4.5 3.7 120.9% View Chart
Dividend Yield % 0.1 1.0 10.2%  

Financials

 IPCA LABS   ALEMBIC PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ALEMBIC PHARMA
Mar-19
IPCA LABS/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs695664 104.7%   
Low Rs400412 97.0%   
Sales per share (Unadj.) Rs260.2208.7 124.7%  
Earnings per share (Unadj.) Rs19.031.0 61.2%  
Cash flow per share (Unadj.) Rs33.137.1 89.1%  
Dividends per share (Unadj.) Rs1.005.50 18.2%  
Dividend yield (eoy) %0.21.0 17.9%  
Book value per share (Unadj.) Rs213.0144.2 147.7%  
Shares outstanding (eoy) m126.20188.52 66.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.12.6 81.6%   
Avg P/E ratio x28.917.4 166.3%  
P/CF ratio (eoy) x16.614.5 114.3%  
Price / Book Value ratio x2.63.7 68.9%  
Dividend payout %5.317.7 29.7%   
Avg Mkt Cap Rs m69,120101,461 68.1%   
No. of employees `00013.3NA-   
Total wages/salary Rs m7,3597,467 98.6%   
Avg. sales/employee Rs Th2,477.4NM-  
Avg. wages/employee Rs Th555.2NM-  
Avg. net profit/employee Rs Th180.6NM-  
INCOME DATA
Net Sales Rs m32,83639,347 83.5%  
Other income Rs m41894 445.6%   
Total revenues Rs m33,25439,441 84.3%   
Gross profit Rs m4,5058,736 51.6%  
Depreciation Rs m1,7771,152 154.2%   
Interest Rs m240184 130.5%   
Profit before tax Rs m2,9057,493 38.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,568 32.6%   
Profit after tax Rs m2,3945,844 41.0%  
Gross profit margin %13.722.2 61.8%  
Effective tax rate %17.620.9 84.1%   
Net profit margin %7.314.9 49.1%  
BALANCE SHEET DATA
Current assets Rs m19,45519,577 99.4%   
Current liabilities Rs m10,07614,896 67.6%   
Net working cap to sales %28.611.9 240.1%  
Current ratio x1.91.3 146.9%  
Inventory Days Days9890 109.1%  
Debtors Days Days6745 147.6%  
Net fixed assets Rs m20,26027,097 74.8%   
Share capital Rs m252377 66.9%   
"Free" reserves Rs m26,63326,811 99.3%   
Net worth Rs m26,88627,188 98.9%   
Long term debt Rs m2,3404,993 46.9%   
Total assets Rs m41,17347,778 86.2%  
Interest coverage x13.141.7 31.4%   
Debt to equity ratio x0.10.2 47.4%  
Sales to assets ratio x0.80.8 96.8%   
Return on assets %6.412.6 50.7%  
Return on equity %8.921.5 41.4%  
Return on capital %10.823.6 45.6%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64219,453 80.4%   
Fx outflow Rs m4,8846,065 80.5%   
Net fx Rs m10,75913,388 80.4%   
CASH FLOW
From Operations Rs m3,4118,120 42.0%  
From Investments Rs m-1,354-7,556 17.9%  
From Financial Activity Rs m-1,304590 -220.9%  
Net Cashflow Rs m7531,153 65.3%  

Share Holding

Indian Promoters % 45.9 74.1 61.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 2.9 393.1%  
FIIs % 25.3 9.1 278.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 13.9 125.2%  
Shareholders   36,892 49,328 74.8%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Sensex Zooms 1,250 Points(12:30 pm)

Share markets in India are presently trading on a strong note, cheering the government's move to cut corporate tax rates to boost economic growth.

Related Views on News

ALEMBIC PHARMA Surges by 9%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Sep 23, 2019 | Updated on Sep 23, 2019

ALEMBIC PHARMA share price has surged by 9% and its current market price is Rs 568. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are ALEMBIC PHARMA (up 9.1%) and ABBOTT INDIA (up 6.3%). The top losers are ALKEM LABORATORIES (down 0.1%) and BIOCON (down 0.2%).

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 23, 2019 02:39 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS